Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study

Archives of Internal Medicine

Volumn 165, Issue 9, 2005, Pages 978-984

  Johnsen, Søren P ^a,b   Larsson, Heidi ^a   Tarone, Robert E ^c,d   McLaughlin, Joseph K ^c,d   Nørgård, Bente ^a   Friis, Søren ^e   Sørensen, Henrik T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ETODOLAC; GLUCOCORTICOID; GOLD; IBUPROFEN; INSULIN; MELOXICAM; NABUMETONE; NAPROXEN; NITRATE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PENICILLAMINE; PHENPROCOUMON; ROFECOXIB; WARFARIN;

ADULT; AGED; ALCOHOLISM; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC BRONCHITIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; EMPHYSEMA; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE INHIBITORS; DENMARK; FEMALE; HOSPITALIZATION; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRAZOLES; RISK ASSESSMENT; SULFONAMIDES; SULFONES;

EID: 18344368896     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.9.978     Document Type: Review

References (37)

1. Merck announces voluntary worldwide withdrawal of VIOXX. News release. Whitehouse Station, NJ: Merck; 2004. Available at: http://www.vioxx.com/vioxx/ documents/english/vioxx_press_release.pdf Accessed September 30, 2004.
2. FDA statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex. Rockville, Md: US Food and Drug Administration; December 17, 2004. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01144.html.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345:433-442.
4. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Pharmacoepidemiol Drug Saf. 2003;12:67-70.
5. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet. 2004;364:639-640.
6. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364:2021-2029.
7. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343: 1520-1528.
8. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
9. Solomon DH, Glynn RJ, Levin R, Avorn J. Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002; 162:1099-1104.
10. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
11. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002; 162:1111-1115.
12. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
13. Reicin A, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89:204-209.
14. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-2073.
15. Ray WA, Stein MC, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360: 1071-1073.
16. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003; 163:481-486.
17. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157-164.
18. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins D. Selective cyclooxygenase-2 inhibition and cardiovascular effects. Arch Intern Med. 2005; 165:181-186.
19. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365: 475-481.
20. Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
21. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004;364:675-684.
22. FDA Statement on Naproxen. Rockville, Md: US Food and Drug Administration; December 20, 2004. Available at: http://www.fda.gov/bbs/topics/ news/2004/NEW01148.html.
23. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Dan Med Bull. 1999;46:263-268.
24. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies, I: principles. Am J Epidemiol. 1991;134: 433-437.
25. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003; 56:124-130.
26. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sørensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199-205.
27. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2 specific inhibitors or non-specific NSAIDs: data from real-life practice. Am J Manag Care. 2002;8(15 suppl):S392-S400.
28. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 2002;47:595-602.
29. Mellemkjær L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAID: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002;53:173-181.
30. Ray W. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
31. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004; 363:1751-1756.
32. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
33. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCES-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002; 90:959-963.
34. White WB, Faich G, Whelton A. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89:425-430.
35. Schlienger RG, Jick H, Meier CR. Use of anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol. 2002; 54:327-332.
36. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational study. Lancet. 2002;359:118-123.
37. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299:1247-1250.